Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorit Di Gioia

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 26, 2016
Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3Dorit Di Gioia, Irene Blankenburg, Dorothea Nagel, et al.
Deutsche Medizinische Wochenschrift (1946)|February 27, 2024
[Current therapeutic standards in advanced soft tissue sarcomas]Anton Burkhard-Meier, Luc M Berclaz, Dorit Di Gioia, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 3, 2014
Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancerDorit Di Gioia, Marie Dresse, Doris Mayr, et al.
World Journal of Surgical Oncology|January 12, 2022
Sarcomas of the extremities and the pelvis: comparing local recurrence after incisional and after core-needle biopsyAlexander Klein, Christof Birkenmaier, Julian Fromm, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 11, 2015
Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patientsPetra Stieber, Dorothea Nagel, Irene Blankenburg, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 14, 2014
Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancerDorit Di Gioia, Marie Dresse, Doris Mayr, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 10, 2011
Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)Dorit Di Gioia, Volker Heinemann, Dorothea Nagel, et al.
Radiation Oncology (London, England)|March 27, 2021
MR-guided stereotactic body radiation therapy for primary cardiac sarcomasStefanie Corradini, Rieke von Bestenbostel, Angela Romano, et al.
Anti-Cancer Drugs|October 7, 2022
Treatment of metastatic alveolar soft part sarcoma with axitinib and pembrolizumab in an 80-year-old patient with a history of autoimmune disordersKlara Dorman, Anton Burkhard-Meier, Dorit Di Gioia, et al.
Frontiers in Oncology|November 4, 2024
Surgical site infections after sarcoma resections in the peripelvic region: do we need perioperative antibiotic prophylaxis?Alexander Klein, Chataut Chudamani, Andreas Wieser, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 26, 2016
Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3Dorit Di Gioia, Irene Blankenburg, Dorothea Nagel, et al.
Deutsche Medizinische Wochenschrift (1946)|February 27, 2024
[Current therapeutic standards in advanced soft tissue sarcomas]Anton Burkhard-Meier, Luc M Berclaz, Dorit Di Gioia, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 3, 2014
Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancerDorit Di Gioia, Marie Dresse, Doris Mayr, et al.
World Journal of Surgical Oncology|January 12, 2022
Sarcomas of the extremities and the pelvis: comparing local recurrence after incisional and after core-needle biopsyAlexander Klein, Christof Birkenmaier, Julian Fromm, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 11, 2015
Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patientsPetra Stieber, Dorothea Nagel, Irene Blankenburg, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 14, 2014
Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancerDorit Di Gioia, Marie Dresse, Doris Mayr, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 10, 2011
Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)Dorit Di Gioia, Volker Heinemann, Dorothea Nagel, et al.
Radiation Oncology (London, England)|March 27, 2021
MR-guided stereotactic body radiation therapy for primary cardiac sarcomasStefanie Corradini, Rieke von Bestenbostel, Angela Romano, et al.
Anti-Cancer Drugs|October 7, 2022
Treatment of metastatic alveolar soft part sarcoma with axitinib and pembrolizumab in an 80-year-old patient with a history of autoimmune disordersKlara Dorman, Anton Burkhard-Meier, Dorit Di Gioia, et al.
Frontiers in Oncology|November 4, 2024
Surgical site infections after sarcoma resections in the peripelvic region: do we need perioperative antibiotic prophylaxis?Alexander Klein, Chataut Chudamani, Andreas Wieser, et al.
Pageof 5